W7

W 7 is a biochemical.

W-7 hydrochloride (W-7 HCl), a calmodulin antagonist, inhibits Ca2+-calmodulin-dependent myosin light chain kinase and phosphodiesterase, W-7 hydrochloride induces apoptosis and has antitumor activity.

Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.

GW7604 is an antiestrogen and it also is the metabolite of GW5638. GW5638 is an antagonist of high-affinity estrogen receptor (ER).

GW 7647 is an effective and highly selective PPARα agonist, the EC 50 values of human PPARα, PPARγ and PPARδ receptors are 6,1100 and 6200 nM, respectively. GW 7647 can reduce the production of nitric oxide in macrophages and has lipid-lowering and anti-inflammatory properties in the body.

JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling pathway (IC50: 420 nM).

GW788388 is a potent and selective inhibitor of ALK5, and it also inhibits TGF-(beta) type II receptor and activin type II receptor activities.

BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

GW780056X is a selective inhibitor of cyclin-dependent kinase. GW780056X is also an inhibitor of Yes1 kinase. It is an inhibitor of binding or entry into cells for the Lassa Virus.

GW7845, an L-tyrosine derivative, is a PPAR-γ agonist.

W7477 is a biochemical.

NVP-ADW742 (ADW) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

GW791343 trihydrochloride (GW791343 3HCl) is aHCl salt form of GW791343, which is a non-competitive allosteric modulator of human P2X7 receptor inhibitor with pIC50 of 7.

GW791343 dihydrochloride (GW791343 (HCl)) is a P2X7 allosteric modulator.

DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.

GW701427A is a dual inhibitor targeting Fluc and VEGFR2, with IC50 values of 0.12 μM and 603 nM, respectively. It functions as a protein kinase inhibitor on both ATP-dependent and -independent luciferases, potentially affecting Fluc reporter assays [1].

GW759710A is a FLuc inhibitor (IC50: 0.73 μM) [1].

GW779439X is a pyrazolopyridazine compound that inhibits the S. aureus kinase Stk1 and Aurora kinase A (AURKA). It restores the efficacy of β-lactam antibiotics against methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) S. aureus, often re-sensitizing resistant strains. This antibacterial potentiation is achieved through the induction of apoptosis via caspase-3/7 pathway activation.

Anti-SARS-CoV-2 Spike Antibody (7W739) is a Rabbit IgG monoclonal antibody targeting SARS-CoV-2 SARS-CoV-2 Spike.

Anti-EGF Antibody (5W778) is a Rabbit IgG monoclonal antibody targeting Human EGF.

LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.